Moderna’s personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread when used in combination with the U.S. drugmaker’s blockbuster treatment Keytruda in a late-stage ​trial.

The interim results showed statistically significant improvement versus Keytruda alone…

“It is a big deal for the field in general. If this trial was negative, the field of mRNA-based ​cancer therapies and cancer vaccination may never have recovered. With this positive study, there is hope (and likely ​investment to follow) that these approaches may change the way we treat cancer more broadly.”…

"Expect the vaccine for melanoma to enter the market in 2027…

…manufacturing personalized vaccines at scale could be expensive and complex. Investors should therefore watch for next important steps, which will be detailed clinical results, ⁠regulatory progress ​and evidence that the technology works across other cancers."…